Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review.

Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, Sigurdsson G, Danesh J, Gudnason V.

PLoS Med. 2010 May 25;7(5):e1000278. doi: 10.1371/journal.pmed.1000278. Review.

2.

Salivary immunoglobulins and prevalent coronary artery disease.

Janket S, Meurman JH, Baird AE, Qvarnström M, Nuutinen P, Ackerson LK, Hong J, Muthukrishnan P, Van Dyke TE.

J Dent Res. 2010 Apr;89(4):389-94. doi: 10.1177/0022034509359884. Epub 2010 Feb 22.

3.

Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis.

Abdul-Salam VB, Ramrakha P, Krishnan U, Owen DR, Shalhoub J, Davies AH, Tang TY, Gillard JH, Boyle JJ, Wilkins MR, Edwards RJ.

Arterioscler Thromb Vasc Biol. 2010 May;30(5):1027-33. doi: 10.1161/ATVBAHA.109.199810. Epub 2010 Feb 18.

4.

Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective study.

Conen D, Rexrode KM, Creager MA, Ridker PM, Pradhan AD.

Circulation. 2009 Sep 22;120(12):1041-7. doi: 10.1161/CIRCULATIONAHA.109.863092. Epub 2009 Sep 8.

5.

Value of p-value in biomedical research.

Panagiotakos DB.

Open Cardiovasc Med J. 2008;2:97-9. doi: 10.2174/1874192400802010097. Epub 2008 Nov 18.

6.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group..

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
7.

Results from the Periodontitis and Vascular Events (PAVE) Study: a pilot multicentered, randomized, controlled trial to study effects of periodontal therapy in a secondary prevention model of cardiovascular disease.

Offenbacher S, Beck JD, Moss K, Mendoza L, Paquette DW, Barrow DA, Couper DJ, Stewart DD, Falkner KL, Graham SP, Grossi S, Gunsolley JC, Madden T, Maupome G, Trevisan M, Van Dyke TE, Genco RJ.

J Periodontol. 2009 Feb;80(2):190-201. doi: 10.1902/jop.2009.080007 .

8.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group..

N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.

9.

Inflammation, C-reactive protein, and atherothrombosis.

Ridker PM, Silvertown JD.

J Periodontol. 2008 Aug;79(8 Suppl):1544-51. doi: 10.1902/jop.2008.080249. Review.

PMID:
18673009
10.

Salivary lysozyme and prevalent hypertension.

Qvarnstrom M, Janket S, Jones JA, Nuutinen P, Baird AE, Nunn ME, Van Dyke TE, Meurman JH.

J Dent Res. 2008 May;87(5):480-4.

11.

Why must new cardiovascular risk factors be carefully re-assessed prior to clinical application?

Janket SJ, Shen Y, Baird AE.

Eur Heart J. 2008 May;29(10):1336-7; author reply 1337. doi: 10.1093/eurheartj/ehn151. Epub 2008 Apr 15. No abstract available.

PMID:
18417456
12.

New cardiovascular risk factors exist, but are they clinically useful?

Wang TJ.

Eur Heart J. 2008 Feb;29(4):441-4. doi: 10.1093/eurheartj/ehm644. Review.

PMID:
18276617
13.

Oral infection, hyperglycemia, and endothelial dysfunction.

Janket SJ, Jones JA, Meurman JH, Baird AE, Van Dyke TE.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Feb;105(2):173-9. Epub 2007 Oct 1. Review.

14.

Lysozyme refolding with cyclodextrins: structure-activity relationship.

Desai A, Lee C, Sharma L, Sharma A.

Biochimie. 2006 Oct;88(10):1435-45. Epub 2006 May 24.

PMID:
16737767
15.

What does minor elevation of C-reactive protein signify?

Kushner I, Rzewnicki D, Samols D.

Am J Med. 2006 Feb;119(2):166.e17-28. Review.

PMID:
16443421
16.

Salivary lysozyme and prevalent coronary heart disease: possible effects of oral health on endothelial dysfunction.

Janket SJ, Meurman JH, Nuutinen P, Qvarnström M, Nunn ME, Baird AE, Van Dyke TE, Jones JA.

Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):433-4. No abstract available.

17.

Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: association with periodontitis.

Karima M, Kantarci A, Ohira T, Hasturk H, Jones VL, Nam BH, Malabanan A, Trackman PC, Badwey JA, Van Dyke TE.

J Leukoc Biol. 2005 Oct;78(4):862-70. Epub 2005 Aug 4.

18.

A prospective study of fruit and vegetable intake and the risk of type 2 diabetes in women.

Liu S, Serdula M, Janket SJ, Cook NR, Sesso HD, Willett WC, Manson JE, Buring JE.

Diabetes Care. 2004 Dec;27(12):2993-6. No abstract available.

PMID:
15562224
19.

Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.

Pickup JC.

Diabetes Care. 2004 Mar;27(3):813-23. Review.

PMID:
14988310
20.

Asymptotic dental score and prevalent coronary heart disease.

Janket SJ, Qvarnström M, Meurman JH, Baird AE, Nuutinen P, Jones JA.

Circulation. 2004 Mar 9;109(9):1095-100. Epub 2004 Feb 16.

Supplemental Content

Support Center